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Abstract
 
Distinct dendritic cell (DC) subsets have been suggested to be preprogrammed to direct either T
helper cell (Th) type 1 or Th2 development, although more recently different pathogen prod-
ucts or stimuli have been shown to render these DCs more flexible. It is still unclear how dis-
tinct mouse DC subsets cultured from bone marrow precursors, blood, or their lymphoid tissue
counterparts direct Th differentiation. We show that mouse myeloid and plasmacytoid precursor
DCs (pDCs) cultured from bone marrow precursors and ex vivo splenic DC subsets can induce
the development of both Th1 and Th2 effector cells depending on the dose of antigen. In gen-
eral, high antigen doses induced Th1 cell development whereas low antigen doses induced Th2
cell development. Both cultured and ex vivo splenic plasmacytoid-derived DCs enhanced
 
CD4
 
  
 
T cell proliferation and induced strong Th1 cell development when activated with the
Toll-like receptor (TLR)9 ligand CpG, and not with the TLR4 ligand lipopolysaccharide (LPS).
The responsiveness of plasmacytoid pDCs to CpG correlated with high TLR9 expression simi-
larly to human plasmacytoid pDCs. Conversely, myeloid DCs generated with granulocyte/mac-
rophage colony-stimulating factor enhanced Th1 cell development when stimulated with LPS as
a result of their high level of TLR4 expression. Polarized Th1 responses resulting from high an-
tigen dose were not additionally enhanced by stimulation of DCs by TLR ligands. Thus, the net
effect of antigen dose, the state of maturation of the DCs together with the stimulation of DCs
by pathogen-derived products, will determine whether a Th1 or Th2 response develops.
Key words: dendritic cell • Th1 • Th2 • TLR • cytokines
 
Introduction
 
Effective eradication of pathogens requires the intricate in-
terplay between the innate and adaptive immune responses.
In this, dendritic cells (DCs)
 
* 
 
are crucial because they are a
unique group of bone marrow–derived leukocytes that are
specialized for the uptake, transport, processing, and pre-
sentation of antigen to T cells (1–4). At an immature stage
DCs act as sentinels, continuously take up antigen, and be-
come activated by microbial products to secrete proin-
flammatory cytokines. This results in up-regulation of co-
stimulatory molecules required for the effective interaction
with T cells upon migration of the DCs to the lymph
 
nodes. Triggering of T cells into cell cycle progression result-
ing in massive clonal expansion, is a central function of DCs.
DC subsets have been suggested to be preprogrammed
to direct the differentiation of CD4
 
  
 
T cells into either
IFN-
 
 
 
–producing Th1 cells or IL-4–producing Th2 cells
(5–9; for review see 2). Human monocyte–derived DCs
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activated with CD40 ligand were found to induce Th1 dif-
ferentiation (5) whereas DCs derived from CD4
 
  
 
CD3
 
 
 
CD11c
 
  
 
plasmacytoid cells activated with CD40 ligand
induced Th2 differentiation (5). In vivo, mouse antigen–
pulsed splenic CD11c
 
  
 
CD8
 
 
 
  
 
CD11b
 
  
 
DCs induced the
development of Th1 cells whereas CD11c
 
  
 
CD8
 
 
 
 
 
CD11b
 
  
 
DCs induced the development of Th2 cells
when injected into mice (6, 8). However, these DCs had
received maturation signals either in vitro (overnight cul-
ture in GM-CSF; reference 8) or in vivo (Flt3 ligand ad-
ministration; reference 6). Conversely, both subsets of
DCs when freshly isolated directed Th1 cell development
in vitro (7). Taken together, these studies suggest that
these DC subsets may not have an intrinsic capacity to di-
rect either Th1 or Th2 cell development, but rather
might be modified by external factors. Indeed, DC subsets
can be influenced by a range of stimuli including patho-
gen-derived products and inflammatory mediators like
cytokines to impact the subsequent Th cell response (5,
10–26).
A wide range of DCs, when appropriately stimulated, di-
rect the development of Th1 cells largely by their produc-
tion of IL-12 and/or IFN-
 
  
 
(5, 12, 14, 17, 18, 22, 23, 27).
IL-12 production by DCs can be stimulated by a large
range of microbial products and augmented by CD40 liga-
tion or cytokines (10–12, 15, 16, 18–24). However, DCs
may produce IL-12 temporarily and become refractory to
additional stimuli for the production of IL-12, and this has
been referred to as “exhaustion” (23) or “paralysis” (24).
Thus, previously stimulated DCs (23, 24) could help skew
the balance toward a Th0 or Th2 response. In addition, al-
though certain signals stimulate DCs to induce the devel-
opment of Th1 cells, others, such as prostaglandin E2 (28),
cholera toxin, nematode worm, or yeast products will trig-
ger these DCs to direct Th2 development (13, 25, 26, 29).
Thus, pathogen-derived products and/or inflammatory
mediators may clearly affect the ability of DCs to direct
Th1 or Th2 cell development.
Recognition of some pathogen-derived products in-
volves specific receptors, such as the Toll-like receptors
(TLRs), which were initially identified in Drosophila but
are also expressed in vertebrates (30–32). In human, distinct
DC subsets have been shown to express different TLRs and
consequently to respond to distinct microbial products (33–
35). For example, monocyte-derived DCs express TLR2
and TLR4 whereas plasmacytoid precursor DCs (pDCs)
express TLR7 and TLR9 (33–35). An inability to produce
IL-12 or IFN-
 
  
 
upon stimulation with specific microbial
products may therefore reflect the lack of expression of the
corresponding TLR and hence their ability to direct Th1
development (30, 31, 33–36).
In addition to pathogen-derived products, the strength
of signal and/or the antigen dose can affect the develop-
ment of Th1 or Th2 cells (23, 37–40). Thus, it is possible
that distinct DC subsets, by their expression of different
levels of MHC class II and/or costimulatory molecules,
may change the effective dose of antigen presented by the
APC to the T cell. It is therefore important that a range of
 
antigen doses be examined when assessing the ability of DC
subsets to direct Th cell development.
In this study we show that both mouse classical and plas-
macytoid pDCs generated from bone marrow as well as
lymphoid tissue DCs can direct Th1 or Th2 responses de-
pending on the dose of antigen presented. Moreover, LPS
and CpG showed differential effects on the different DC
populations to direct Th1 development as a result of differ-
ential expression of TLR4 and TLR9.
 
Materials and Methods
 
Mice.
 
DO11.10 mice transgenic for an OVA
 
323–339
 
-specific
 
  
 
TCR were used as a source of antigen-specific T cells (41).
BALB/c mice (Taconics or NIMR) were used to provide DCs.
All mice were housed under specific pathogen-free conditions.
Female mice were used between 8–12-wk of age.
 
Reagents.
 
mAbs used for T cell preparation were anti-B220,
anti-CD8
 
 
 
, anti-CD11b, anti–CD4-FITC, and anti–CD62L-PE
(all mouse specific; BD Biosciences). mAbs used for the prepara-
tion of DC subsets were anti-erythrocyte (Ter119), anti-CD3
(17A2), anti-CD19 (1D3), B220-FITC, anti–CD11c-PE, anti–
CD11b-APC, anti–CD8
 
 
 
-APC, B220-FITC, and GR1-APC.
Anti–IL-12p40 (C17.8.20) mAbs were used in culture. mAbs
used for intracellular staining were anti–IFN-
 
 
 
–APC (XMG1.2),
anti–IL-4–PE (11B11), and isotype controls (all from BD Bio-
sciences). Culture medium was RPMI 1640 with 10% heat-inac-
tivated FCS, 0.05 mM 2-mercaptoethanol, 10mM Hepes
buffer, 100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin, 2 mM
 
l
 
-glutamine, and 1mM sodium pyruvate or culture medium spe-
cifically made for NIMR by GIBCO BRL. Endotoxin-free OVA
peptide (chicken OVA
 
323–339
 
) was from Biosynthesis. DCs were
stimulated with LPS 
 
Salmonella minnesota
 
 serotype Re595 (Sigma-
Aldrich) or phosphorothioate CpG DNA (CpG1668: TCCAT-
GACGTTCCTGATGCT; Invitrogen). Mouse Flt3 ligand was
produced at DNAX and mouse GM-CSF was obtained from
Schering-Plough.
 
Generation of Bone Marrow–derived DCs.
 
Bone marrow cells
were isolated by flushing femurs and tibia with culture medium.
Red blood cells were lysed using 0.83% ammonium chloride.
CD11c
 
  
 
CD11b
 
  
 
DCs were generated using GM-CSF as de-
scribed by Inaba et al. (42). In brief, bone marrow cells were
plated at 10
 
6 
 
cells/ml in medium supplemented with 10 ng/ml
GM-CSF in 12-well plates in a volume of 2 ml. At days 2 and 4,
supernatant containing nonadherent cells were removed, the
wells were washed gently, and fresh medium containing GM-
CSF was added. At day 6, nonadherent cells were collected, cen-
trifuged, resuspended in fresh medium with GM-CSF, and cul-
tured for an additional 24 h in Petri dishes. Cells were sorted as
CD11c
 
  
 
cells. Plasmacytoid pDCs were generated by culturing
bone marrow cells in culture medium containing 100 ng/ml Flt3
ligand for 10 d at 10
 
6 
 
cells/ml in 12-well plates in a volume of 2
ml. At day 5, 1 ml medium was replaced by 1 ml fresh medium
containing Flt3 ligand (43). Plasmacytoid pDCs generated with
Flt3 ligand were sorted as CD11c
 
  
 
CD11b
 
  
 
B220
 
 
 
. The purity
was always 
 
 
 
98%.
 
Preparation of Splenic DC Subsets.
 
For the purification of
splenic DCs, spleens were treated for 30 min at 37
 
 
 
C with 0.4
mg/ml Liberase Cl (Boehringer), followed by red blood cell lysis
using 0.83% ammonium chloride. Cells were maintained
throughout the procedure in cold PBS, 5% FCS, and 0.5 mM
EDTA. The spleen cells were incubated with anti-CD3, anti-T
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CD19, and anti-Ter119 mAb, followed by goat anti–rat Ig–
coated beads (BioMag Laboratory and Polysciences). The en-
riched DCs were either stained with CD11c-PE and CD8
 
 
 
-
APC, or B220-FITC, CD11c-PE, and GR1-APC, and sorted
using a FACSVantage™ (Becton Dickinson) or MoFlo
 
® 
 
cytome-
ter (DakoCytomation). The purity was always 
 
 
 
98%.
 
Preparation of T Cells.
 
CD4
 
  
 
T cells were enriched from
DO11.10 spleen cell preparations by negative depletion using a
cocktail of anti-CD8
 
 
 
, anti-B220, and anti-CD11b mAb, fol-
lowed by goat anti–rat Ig–coated beads. Enriched CD4
 
  
 
T cells
were then additionally purified using a FACSVantage™ (Becton
Dickinson) or MoFlo
 
® 
 
cytometer (DakoCytomation) to achieve
 
 
 
99% naive CD4
 
  
 
T cells on the basis of bright CD62L and
CD4 staining (44).
 
Stimulation of Transgenic CD4
 
  
 
T Cells for Cytokine Production.
 
Naive CD4
 
  
 
T cells (10
 
5 
 
cells/well) were cultured with purified
DC subsets (2 
 
  
 
10
 
4 
 
cells/well) in a total volume of 1 ml in 48-
well plates. CD4
 
  
 
T cells were obtained from DO11.10 mice
whereas DCs were from BALB/c mice. Cultures were performed
with 10, 1, 0.1, or 0.01 
 
 
 
M OVA peptide. To some cultures 10
 
 
 
g/ml anti–IL-12p40 mAb, 25 
 
 
 
g/ml LPS, or 1 
 
 
 
M CpG DNA
was added. Cells were split on day 4. On days 6–8, cells were har-
vested, washed, counted, and restimulated with 50 ng/ml PMA
and 500 ng/ml ionomycin (both from Sigma-Aldrich; reference
45). After 2 h of incubation, 10 
 
 
 
g/ml brefeldin A (Epicentre
Technologies) was added and the cells were incubated for another
2 h followed by fixation with 2% formaldehyde and permeabiliza-
tion with 0.5% saponin. The cells were stained as previously de-
scribed (45). The samples were measured on a FACSCalibur
 
®
 
flow cytometer (Becton Dickinson) and analyzed using CellQuest
software (Becton Dickinson).
 
T Cell Proliferation Assay.
 
For OVA-specific CD4
 
  
 
Mel14
 
  
 
T
cell proliferation, DC subsets (BALB/c) were 
 
  
 
irradiated (1,500
rad), washed, and cocultured with CD4
 
  
 
Mel14
 
  
 
T cells
(DO11.10), which were added at 10
 
4 
 
cells/well in a volume of
200 
 
 
 
l in round-bottom plates. After 60 h, cells were pulsed for
18 h with 1 
 
 
 
Ci [
 
3
 
H]thymidine before they were collected and
counted. Titration of the OVA peptide dose was with 10
 
3 
 
DCs/
well and 10
 
4 
 
T cells/well. Titration of the DC numbers was with
2.5 
 
  
 
10
 
4 
 
T cells/well and 1 
 
 
 
M OVA peptide.
 
In Vitro Stimulation of DCs and Quantitation of Cytokine Produc-
tion.
 
7 
 
  
 
10
 
4 
 
sorted DCs were cultured in 200 
 
 
 
l in 96-well
flat-bottom culture plates and stimulated with medium alone,
25 
 
 
 
g/ml LPS, or 1 
 
 
 
M CpG DNA. After 24 h, supernatants
of the cell cultures were collected and IL-12p70 levels were
determined by commercially available ELISA kits (BD Bio-
sciences).
 
Quantitative mRNA Analysis for TLR4 and TLR9.
 
RNA from
different DC subsets was extracted using an RNeasy Kit
(QIAGEN) according to the manufacturer’s protocol and reverse
transcribed with oligo dT14-18 (Life Technologies) and random
hexamer primers (Promega). cDNA was analyzed for the expres-
sion of TLR4, TLR9, and 18s by PCR assay using the Per-
kinElmer 5700 Sequence Detection System (PerkinElmer).
Quantification of the target gene expression was by comparison
with 18s rRNA expression using a VIC-labeled probe. The
primer sequences were as follows: forward TLR4 primer TGA
CAG GAA ACC CTA TCC AGA GTT, reverse TLR4 primer
TCT CCA CAG CCA CCA GAT TCT, probe TLR4 TTC
CCC AGG AAG TTT CTC TGG ACT AAC AAG TTTA;
forward TLR9 primer AGC TTC CTG CTG GCT CAGC, re-
verse TLR9 primer GGA CGC AGG ATC ACC AAC AC,
probe TLR9 TGT TGG AAG ACC GCA AGG ACG TGG.
 
Results and Discussion
 
Bone Marrow–derived Myeloid DCs, but not Plasmacytoid
pDCs, Induce Significant T Cell Proliferation: both DC Subsets
Induce Th1 or Th2 Cell Development Depending on the Antigen
Dose.
 
Distinct DC subsets have been suggested to be pre-
programmed to direct Th1 or Th2 cell development. Most
studies addressing whether DCs have an intrinsic capacity
to direct Th1 or Th2 development, or do so as a result of
stimulation by microbial products or other environmental
signals (12, 14, 17, 19, 23), have been performed with cul-
tured human DC populations including monocyte- or plas-
macytoid-derived DCs (5, 17, 23). In this, mouse bone
marrow–derived DCs have been studied to a limited extent
(13) and no studies have been reported on plasmacytoid-
derived DCs with respect to Th cell development. Mouse
CD11c
 
  
 
CD11b
 
  
 
myeloid DCs were obtained from bone
Figure 1. The differential development of naive CD4  T cells by bone
marrow–derived DC subsets into a Th1 or Th2 phenotype depends on
the antigen dose. Bone marrow cells were cultured for 7 d with GM-CSF
to generate CD11c  CD11b  B220  myeloid DCs or for 10 d with Flt3
ligand to generate CD11c  CD11b  B220  plasmacytoid pDCs. (A) Pro-
liferation of CD4  CD62L  T cells obtained from DO11.10 mice stimu-
lated by FACS®-purified CD11c  myeloid DCs or CD11c  B220  plas-
macytoid pDCs was assessed after 60 h in the presence of 1  M OVA
peptide and varying DC numbers (left) or different OVA peptide doses
(right). (B) To assess Th cell development, GM-CSF and Flt3 ligand–
generated bone marrow–derived DC subsets were cocultured with naive
DO11.10 CD4  T cells in the presence of 10, 1, 0.1, or 0.01  M OVA
peptide. After 9 d, cells were washed, counted, and restimulated with
PMA and ionomycin. The cytokine profile was determined by intracellu-
lar cytokine staining for IL-4 and IFN-  using flow cytometry.T
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marrow precursors by culturing in GM-CSF (42) and were
purified by flow cytometry on the basis of CD11c
 
  
 
(all
were CD11b
 
 
 
). Additionally, plasmacytoid pDCs express-
ing CD11c
 
  
 
CD11b
 
  
 
B220
 
  
 
were purified by flow cytom-
etry after culture of bone marrow cells in the presence of
Flt3 ligand (43). Myeloid DCs induced higher proliferation
of OVA-specific TCR transgenic CD4  T cells than plas-
macytoid pDCs (Fig. 1 A). This could be explained by the
low expression of MHC class II and costimulatory mole-
cules by plasmacytoid pDCs (43 and unpublished data), and
may reflect differences in the maturation state of the dis-
tinct DC subsets after in vitro culture.
To investigate the ability of myeloid or plasmacytoid
pDCs isolated from bone marrow to induce Th cell devel-
opment, we stimulated naive OVA-specific TCR trans-
genic CD4  T cells using the distinct DC populations at
different doses of OVA peptide. Myeloid DCs generated
from bone marrow with GM-CSF induced Th1 cell devel-
opment (11% IFN-   and 0% IL-4  cells; Fig. 1 B) in the
presence of a high antigen dose (10  M OVA peptide).
Lower OVA peptide concentrations resulted in reduced
Th1 cell development and eventually a weak Th2 response
(18% IL-4  and 1% IFN-   cells) at 0.01  M OVA pep-
tide. Similarly, plasmacytoid pDCs generated from bone
marrow with Flt3 ligand induced the most pronounced
Th1 phenotype in cultures containing high doses of OVA
peptide (31% IFN-   and 1% IL-4  cells). Activation of Th
cells with plasmacytoid pDCs at 1  M OVA peptide led to
a mixed Th1/Th2 phenotype (29% IFN-  , 9% IFN-  /
IL-4 , and 8% IL-4 ). At 0.1  M OVA peptide, a weak
Th2 development was observed (9% IL-4  and 4% IFN-
  ). Plasmacytoid pDCs induced poor proliferation of Th
cells at 0.01  M OVA and consequently did not induce Th
cell polarization. The absolute dose of antigen directing
Th1 or Th2 cell development could vary slightly between
experiments, but the trend was always the same. The ability
of the antigen dose to affect Th cell development (23, 37–
40) could provide an explanation as to why different DC
subsets have been suggested to intrinsically direct Th1 or
Th2 development (5–8), particularly when measured in a
mixed lymphocyte response where the exact dose of anti-
gen cannot be established. Distinct DC subsets at different
stages in maturation may express different levels of MHC
class II and costimulatory molecules, or different amounts
of MHC class II peptide on their surface as a result of dif-
ferential processing, resulting in a different effective antigen
dose leading to altered Th cell development.
Th1 Cell Development Is Enhanced at Medium to Low Anti-
gen Doses Using Bone Marrow–derived Myeloid DCs Stimulated
with LPS or Bone Marrow–derived Plasmacytoid pDCs Stimu-
lated with CpG. To determine whether any pathogen-
derived products could affect the ability of bone marrow–
derived myeloid or plasmacytoid pDCs to direct Th cell
development at medium to low antigen doses, we performed
experiments in the presence of the TLR4 ligand LPS (46,
47) and the TLR9 ligand CpG (48). Here, we show that
myeloid DC stimulated with LPS induced the develop-
ment of Th1 cells (from 7 to 27% IFN-   and 0% IL-4 ;
Fig. 2, top) at 1  M OVA, as previously shown (13). This
is partly blocked by an mAb to IL-12p40 (Fig. 2). CpG
stimulation of myeloid DCs weakly enhanced Th1 cell de-
velopment. On the other hand, plasmacytoid pDCs gener-
ated from bone marrow with Flt3 ligand stimulated with
CpG greatly enhanced T cell proliferation at 1  M OVA
peptide and induced strong Th1 cell development (from
4% IFN-   to 13%; Fig. 2, bottom), but were unresponsive
to LPS to induce T cell proliferation (not depicted) or Th1
development (Fig. 2). The CpG-induced Th1 cell devel-
opment was completely inhibited by anti–IL-12p40 mAb.
At high antigen dose, myeloid and plasmacytoid pDC–
directed Th1 development was not additionally enhanced
by LPS nor CpG (not depicted). However, low dose anti-
gen–induced Th2 development was overridden by LPS and
CpG, respectively, resulting in Th1 development (not de-
picted). Thus, myeloid DCs can respond to the TLR4
ligand LPS and to a small extent the TLR9 ligand CpG,
whereas bone marrow–derived plasmacytoid pDCs can re-
spond to CpG but not LPS to direct Th1 cell development.
It is possible that this differential responsiveness to LPS and
CpG reflects differential expression of TLR4 and TLR9.
Splenic DC Subsets Induce Distinct Th Cell Phenotypes De-
pending on the Antigen Dose. The classical splenic CD11c 
CD8   CD11b  and CD11c  CD8   CD11b  DC sub-
sets have been shown to direct Th1 or Th2 responses in
vivo, respectively (6, 8), but these DCs had been subjected
to maturation in vitro (overnight culture in GM-CSF; ref-
erence 8) or in vivo (Flt3 ligand administration; reference
6). Furthermore, both subsets of splenic DC, when freshly
Figure 2. Myeloid and plasmacytoid bone marrow–derived DCs in-
duce Th1 development with CpG whereas only myeloid DCs are respon-
sive to LPS. FACS®-purified bone marrow–derived DCs were cultured
with 1  M OVA and CD4  Mel14  T cells for 9 d under neutral condi-
tions with LPS or CpG. To some cultures, anti–IL-12p40 mAbs were
added. At day 9, the percentage of IL-4 and IFN-   T cells was deter-
mined by flow cytometry after restimulation with PMA and ionomycin.T
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isolated in vitro, could direct Th1 development (49). The
ability of the more recently described CD11cdull  Gr1 
B220  spleen plasmacytoid pDC (50–52) to direct Th cell
development has not yet been assessed. In addition, the
functional relationship between cultured and lymphoid tis-
sue DCs is unknown and functional similarities to human
DCs have not been considered. To this end, we deter-
mined the effects of antigen dose and microbial products
on the ability of freshly isolated spleen DC subsets to in-
duce Th cell development.
As previously described, freshly isolated and FACS®-
purified splenic classical CD11c  DCs stimulated very sig-
nificant T cell proliferation. In contrast, splenic plasmacytoid
pDCs stimulated very weak to no proliferation of CD4  T
cells (Fig. 3 A), which could be explained by their low ex-
pression of costimulatory (CD40, CD80, CD86, and inter-
cellular adhesion molecule 1) and MHC II molecules (50).
Again, this could reflect different relative levels of matura-
tion of classical CD11cbright and plasmacytoid pDCs.
Titration of the antigen had a similar effect on the abil-
ity of CD11c   CD8    CD11b   and CD11c   CD8  
CD11b  DCs to induce Th cell development (Fig. 3 B). At
high OVA peptide doses, both CD8    CD11b   and
CD8    CD11b   DCs induced Th1 cell development.
Gradual lowering of the antigen dose from 10 to 0.01  M
OVA peptide resulted in reduced Th1 cell development
and the induction of a Th2 phenotype at a low antigen
dose (Fig. 3 B). CD8   CD11b  DCs generally induced a
weaker Th1 phenotype than CD8   CD11b  DCs (24 vs.
36% IFN-   cells, respectively). Again, the absolute level
and number of IFN- –producing cells varied between ex-
periments although the trend always remained the same.
The strong Th1 cell development observed at high antigen
doses may result from higher up-regulation of CD40 ligand
Figure 3. Splenic DC subsets direct Th1 or Th2 cell development of
naive CD4  T cells depending on the antigen dose. (A) Proliferation of
CD4  CD62L  T cells from DO11.10 mice stimulated by FACS®-puri-
fied CD11c  CD8  , CD11c  CD8   DCs, or splenic B220  plasmacy-
toid pDCs was assessed after 60 h in the presence of 1  M OVA peptide
and varying numbers of DCs (left) or titration of the dose of OVA pep-
tide (right). (B) To assess Th cell development, splenic DC subsets were
cocultured with naive CD4  T cells from DO11.10 mice in the presence
of the 10, 1, 0.1, or 0.01  M OVA peptide. After 9 d, cells were washed,
counted, and restimulated with PMA and ionomycin. The cytokine pro-
file was determined by intracellular cytokine staining for IL-4 and IFN- .
Figure 4. Plasmacytoid pDCs and splenic CD8  , but not CD8  ,
DCs direct Th1 cell development with CpG. Classical splenic CD11c 
CD8   and CD11c  CD8   DCs were cultured with 0.01  M OVA
peptide (A and B) or CD11cdull B220  plasmacytoid pDCs with 1  M
OVA peptide (C) in cocultures with CD4  Mel14  T cells for 9 d under
neutral conditions with LPS or CpG DNA. To neutralize endogenous
IL-12, anti–IL-12p40 mAb was added to some cultures. After 9 d, the cy-
tokine profile was determined by flow cytometry.T
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on T cells (15, 16, 53), leading to higher levels of IL-12 or
other Th1-inducing factors. In this respect, anti–IL-12p40
mAb only partially blocked Th1 cell development seen at
high antigen doses (not depicted), which suggests the in-
volvement of other Th1-inducing factors (54).
Splenic plasmacytoid pDCs could not trigger Th cell de-
velopment at any antigen dose used, probably because they
did not induce CD4  T cell proliferation and led to very
low T cell recoveries in culture as a result of low expression
of MHC class II, CD40, and other costimulatory mole-
cules. The proliferation of T cells induced by splenic
B220  plasmacytoid pDCs (freshly isolated at 4 C) was
lower than that of their B220  counterpart cultured from
bone marrow with Flt3 ligand (Fig. 1 A), which perhaps
received some maturation signals during culture at 37 C,
e.g., stromal cell–derived signals. This suggests that the
freshly isolated splenic plasmacytoid pDCs are less mature
and therefore unable to induce T cell proliferation and
drive Th cell development even at high antigen doses.
CpG, but not LPS, Enhanced Th1 Cell Development upon
Stimulation of Splenic CD8   CD11b  DCs and Plasmacytoid
pDCs. Microbial products were examined for their effect
on Th cell development driven by splenic DC subsets.
CpG could induce some Th1 cell development with
CD8   CD11b  DCs at 0.01  M OVA peptide (increase
from 2 to 12% IFN-   cells), which could partly be
blocked by anti–IL-12p40 mAb (Fig. 4). This was not ob-
served with CD8   CD11b  DCs. However, stimulation
with LPS or CpG of both CD8   CD11b  and CD8  
CD11b  DCs resulted in reduced Th2 cell development
and some T cell proliferation (not depicted).
Splenic B220  plasmacytoid pDCs cultured in the pres-
ence of CpG induced expression of MHC class II, costimu-
lators, and CD8  (50), and an 18-fold enhancement of
CD4  T cell proliferation (not depicted), suggesting their
development into mature DCs. CpG-stimulated plasmacy-
toid-derived DCs induced strong Th1 cell development at
1  M OVA peptide (and 10  M; not depicted), which
could be partly blocked with anti–IL-12p40 mAb. The
partial block of Th1 cell development by anti–IL-12p40
mAb, which neutralizes both IL-12 and IL-23 activity (55),
suggests the possible involvement of other cytokines in
Th1 cell development (for review see 54). Again, similarly
to plasmacytoid pDCs isolated from bone marrow, LPS had
no effect on spleen plasmacytoid pDCs to induce CD4  T
cell proliferation or Th1 cell development (not depicted).
Differential Expression of TLR on Mouse DC Subsets.
The differential responses to LPS and CpG of the bone
marrow–derived myeloid and plasmacytoid pDCs as well as
of spleen DC subsets prompted us to examine the expres-
sion of their respective TLRs, TLR4 and TLR9. In keep-
ing with the functional data, TLR4 is expressed at high
levels on bone marrow–derived myeloid DCs but at low
levels on plasmacytoid pDCs and classical splenic DC sub-
sets (Fig. 5 A). In contrast, TLR9 is highly expressed on
bone marrow–derived and spleen plasmacytoid pDCs and
also to a lesser extent on classical spleen DCs and GM-
CSF–cultured myeloid DCs. This differential expression of
TLR4 and TLR9 was reflected by their ability to produce
IL-12p70 in response to their respective ligands (Fig. 5 B).
LPS stimulated bone marrow–derived myeloid DCs ex-
pressing TLR4, but not the other subsets, to produce IL-
12p70. In contrast, CpG stimulated IL-12p70 production
from plasmacytoid pDCs but also by myeloid DCs and
spleen CD8   DCs, which all expressed TLR9.
Concluding Remarks. We have shown that cultured
bone marrow–derived DCs or lymphoid tissue–derived
spleen DCs are remarkably flexible in their ability to direct
the development of Th cells with distinct cytokine profiles.
One major factor in determining this plasticity is the dose
Figure 5. Quantitative real time PCR analysis of TLR4
and TLR9 expression on bone marrow–derived and
splenic DC subsets. (A) Expression is relative to 18s. (B)
7   104 sorted DCs were stimulated in a volume of 200  l
with medium, LPS, or CpG for 24 h. IL-12p70 levels were
determined by immunoassay. The sensitivity of the ELISA
was 25 pg/ml.T
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of antigen. High dose of antigen generally induced the de-
velopment of Th1 responses whereas low dose favored Th2
cell development, regardless of the DC subset. Th1 cell de-
velopment induced with a high antigen dose may reflect a
high level of CD40 ligand expression on the T cell that
may result in enhanced CD40 signaling (53), leading to
higher levels of IL-12 induction.
Mouse plasmacytoid pDCs enhanced CD4  T cell pro-
liferation and induced strong Th1 cell development when
activated with the TLR9 ligand CpG, but not with the
TLR4 ligand LPS. Myeloid DCs cultured with GM-CSF,
on the other hand, drive Th1 cell development after LPS
stimulation. This is explained by our observations that plas-
macytoid pDCs express high levels of TLR9 and low levels
of TLR4 whereas only GM-CSF–cultured myeloid DCs
express TLR4. These results are in good agreement with
published reports of human DC subsets with respect to
TLR expression and DC function. Specifically, human
monocyte–derived DCs express TLR4 and plasmacytoid
pDCs express TLR9 (33–35). However, it should be noted
that mouse TLR9 expression is not restricted to plasmacy-
toid pDCs but is expressed more broadly on other DC sub-
sets. The differential expression of TLR4 and TLR9 on
distinct DC subsets will determine whether they will be
triggered by specific pathogen products to make IL-12 or
other appropriate factors that direct Th1 cell development.
Interestingly, at high antigen dose, Th1 cell development
was not enhanced by LPS nor CpG-stimulated DCs, possi-
bly because the DCs may already be producing maximal
levels of Th1-inducing cytokines as a result of their strong
interaction with T cells. At lower antigen dose, when Th1
development was less pronounced, and even when Th2
development was observed, LPS or CpG-stimulated DCs
did direct Th1 development.
In conclusion, the net effect of the dose of antigen, the
state of maturation of the DC, and of environmental signals
will determine whether naive CD4  T cells develop into
Th1 or Th2 cells. These “plastic” properties of the DC are
in keeping with its role as a sensor to direct appropriate re-
sponses in order to eradicate pathogens with minimum pa-
thology to the host.
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